In comments on the Centers for Medicare & Medicaid Services' advance notice of proposed rulemaking on the International Pricing Index model for Medicare Part B drugs, AHA commends the agency's willingness to address excessive growth in drug prices, but "given the amount of model specifics still to be determined, the anticipated operational burdens, as well as other logistical concerns, the AHA urges CMS to consider narrowing the scope of the program to a more targeted intervention than that described in the ANPRM." AHA's Dec. 27 comments and concerns focused on the ANPRM's impact on hospitals participating in the 340B Drug Pricing Program; regulatory and operational burden; payment reductions; and model vendors' fees and policies. The AHA noted that its primary concern is the model's interaction with the 340B program and asked CMS to hold 340B hospitals harmless under the model. AHA said it looks forward to working with CMS "to improve the IPI model."

Headline
The AHA and its co-plaintiffs Nov. 16 filed a reply brief urging a federal court to block implementation of the Health Resources and Services Administration’s…
Headline
The Centers for Medicare & Medicaid Services Nov. 5 published a final rule to codify the Medicare Drug Price Negotiation Program beginning in 2029. The…
Headline
The estimated average monthly premium for Medicare Part D stand-alone prescription drug plans is $51 for 2027, a 50% increase from $34 in 2026, for enrollees…
Headline
The Department of Labor Oct. 29 finalized a rule designed to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to…
Headline
The AHA Oct. 27 submitted comments on the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B…
Headline
The U.S. District Court for the District of Maine should deny motions by several drug companies and Pharmaceutical Research and Manufacturers of America to…